The best way to stop Mounjaro: what the evidence says before you decide

What trial data tells us about stopping tirzepatide

The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed participants for 72 weeks on tirzepatide and found average body-weight reductions of around 20–21% at the highest doses. A follow-up extension confirmed what researchers already suspected: when the medicine stopped, weight returned, significantly and relatively quickly. That finding is not a reason to stay on treatment indefinitely; it is a reason to plan the end of treatment as carefully as the beginning.

The NHS tirzepatide medicines page is clear that tirzepatide works alongside a reduced-calorie diet and increased activity, not instead of them. Patients who had used the treatment period to build new habits showed better weight maintenance. That is the practical message from the evidence: stopping Mounjaro is not a cliff edge if the foundations were laid during treatment.

None of this means you should stay on Mounjaro if it is no longer appropriate for you. Cost, side effects, a change in health status, or simply reaching a point where you and your prescriber agree it is the right time are all legitimate reasons to stop. The trial data simply argues for a plan rather than an abrupt end.

Does Mounjaro need to be tapered, or can you stop suddenly?

Tirzepatide does not carry a compulsory tapering schedule in the way that corticosteroids or some antidepressants do. The Mounjaro SmPC on the eMC does not mandate a dose step-down before stopping. That said, many prescribers do recommend stepping back through lower doses over a few weeks, and there are reasonable physiological grounds for doing so.

Mounjaro slows gastric emptying and suppresses appetite through dual GIP and GLP-1 receptor activity. Once you stop, those effects fade over roughly a week or two as the medicine clears. Some people notice a fairly sharp return of hunger. A step-down gives your appetite-signalling system a gentler adjustment period and can make the transition easier to manage day to day.

Whether to taper or stop outright is a clinical judgement. If you are looking at the practical steps for stopping Mounjaro, the most important first action is a conversation with the prescriber who oversees your treatment, not a self-directed dose change. They can review whether the timing is right, advise on whether tapering makes sense for you, and check your current health markers before you finish.

What happens to appetite and weight when you stop

Within a few weeks of the final injection, most people notice their appetite returning, often more strongly than it did before treatment. This is not a failure of willpower. Tirzepatide was actively suppressing hunger signals; removing it means those signals come back, sometimes loudly. Knowing this in advance lets you prepare rather than be caught off guard.

A checking habit worth building now, before you stop, is to log one typical day of eating while still on treatment. That record (what felt like a full day, what portions looked like, which meals satisfied you) becomes a useful reference point once the medicine is gone and appetite feels different again. It takes about a minute to note on your phone and can be surprisingly grounding later.

For practical guidance on getting the most from treatment while it lasts, the page on how to lose weight effectively on Mounjaro covers protein targets, activity and the habits most likely to persist after stopping, and you can also read about the best way to take Mounjaro to make sure your injection technique and timing are working as hard as possible before you finish treatment. Building those habits during treatment is specifically what the clinical evidence points to as protective.

Deciding whether stopping is the right call right now

Not everyone stopping Mounjaro is stopping for good. Some people take a planned break (perhaps around surgery, pregnancy planning, or financial reasons) intending to restart later. NICE's appraisal of tirzepatide (TA1026) notes that continuing treatment is reviewed if less than 5% weight loss is achieved after six months at the highest tolerated dose, which gives one formal benchmark. Beyond that, the decision is personal and clinical.

If you are on treatment through a private service and have questions about your current dose or whether continuing makes sense, reviewing the full picture of tirzepatide as a medicine can help frame that conversation. It is also worth exploring what other licensed weight-loss treatments might be appropriate if tirzepatide is no longer the right fit for your situation.

For anyone who has been on Mounjaro a long time and is unsure what the process of stopping looks like from a service perspective, the Mounjaro treatment overview sets out what clinical review involves at each stage. Interest in the medicine has grown considerably in recent years, with coverage such as the Nadine Dorries Mounjaro story bringing wider public attention to how and why people come to use it. And if you have more specific questions about how treatment is managed at num, the FAQs page covers common concerns about aftercare and repeat prescriptions.

If you are not currently on treatment and are weighing up whether to start (knowing you may want to stop at some point) our prescribers are the right people to discuss that with. Check your eligibility and a GPhC-registered prescriber will review your consultation the same day.